中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

ANNOUNCEMENT

APPOINTMENT OF INDEPENDENT INVESTIGATOR AND INDEPENDENT INTERNAL CONTROL CONSULTANT

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**", together with its subsidiary, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated April 14, 24 and 29, 2026 and May 27, 2026 in relation to (i) its change of auditor, and (ii) the resumption guidance for the resumption of trading in the shares of the Company (collectively, the "**Announcements**"). Unless otherwise stated, capitalised terms used in this announcement shall bear the same meanings as those defined in the Announcements.

For the purposes of meeting the Resumption Guidance and seeking legal advice, the Audit Committee has engaged through its legal advisers, Baker Tilly Aranea Forensic Investigation Company Limited ("**BTA**") to conduct a forensic investigation and report on the Fund Investments and Consultancy Payments, and Cheng & Cheng Risk Advisory Services Limited ("**CCRA**") to conduct internal control review in relation to, amongst other things, the Fund Investments and Consultancy Payments.

Each of BTA and CCRA has confirmed to the Audit Committee their independence for the purposes of their engagement, including their independence from any of the connected persons or management of the Company.

In evaluating the appointment of BTA, the Audit Committee has also taken into account the credentials, qualification, experience and resources of BTA including the following:

(i) BTA is an operating entity of Baker Tilly Hong Kong, and Baker Tilly Hong Kong has more than 360 professionals based in Hong Kong (encompassing a 40 strong financial and risk advisory department that includes 11 forensic specialists) and being a member of Baker Tilly International, which ranks amongst the top 10 largest accounting firms worldwide;

(ii) it has an extensive track record of undertaking forensic investigation engagements, including no less than 7 cases involving Hong Kong listed issuers since 2021; and

(iii) all of the three core engagement team members are members of the Hong Kong Institute of Certified Public Accountants ("**HKICPA**") and have over 20 years, 10 years and 5 years of experience respectively, in forensic investigation work (including investigation of transactions that are Mainland China and/or Hong Kong based), further supported by a senior adviser with over 37 years of experience in complex financial crimes investigatory work.

In evaluating the appointment of CCRA, the Audit committee has taken into account the credentials, qualification, experience and resources of CCRA including the following:

(i) CCRA (which has a team of 10 internal control specialists) is the risk advisory branch of Cheng & Cheng Limited, CPA, an accounting firm headquartered in Hong Kong which has over 200 auditors over 40 of which are accountants certified by the HKICPA or other international accounting associations;

(ii) it has considerable experience in conducting internal control reviews including for listing applicants and listed issuers, and its core engagement team members have undertaken internal control reviews (not associated with the regular internal audit function under Code Provision D.2.2 of the Listing Rules) for 5 cases involving Hong Kong listed issuers since 2021; and

(iii) two of the four core engagement team members are members of HKICPA and have over 30 years and 20 years of experience respectively in audit work, information systems management, compliance, corporate risk management and internal control. The remaining two members are members of ACCA and CICPA and have over 10 years and 3 years of experience respectively in audit work and internal control review.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of the key findings and the results of the Forensic Investigation and the Internal Control Review as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, June 5, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.